Block Ace is designed as a high-performance blocking reagent for use in immunological assays such as ELISA and Western blotting. It may also be used for dilution of antibodies and for washing procedures in the above assays.
Block Ace has been shown to have superior performance to 1% BSA in blocking in ELISA assays. In comparison to BSA, Block Ace provides reduced backgrounds and sharper standard curves.
For blocking in ELISA applications, we recommend using a 1/4 dilution of the reconstituted solution.
For blocking in Western Blotting applications, we recommend using the reconstituted solution neat.
For washing applications we recommend a 1/10 dilution of the reconstituted solution, and adding Tween 20 to a level of 0.05-0.2% v/v.
For use as a test sample or secondary antibody diluent we recommend a 1/10 dilution of the reconstituted solution.
Reconstitute each 4g sachet in 100ml distilled water.
Approx. Protein Concentrations
Reagents In The Kit
Preparing The Antibody
Store at +4oC. DO NOT FREEZE. This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
Prior to reconstitution, 2 years from date of despatch. After reconstitution, 1 week at 4oC.
For research purposes only
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the reagent for use in their own system using appropriate negative/positive controls
6. Matsui, T.S. et al. (2011) Non-muscle myosin II induces disassembly of actin stress fibres independently of myosin light chain dephosphorylation.Interface Focus. 1 (5): 754-66.
7. Zhang, B. et al. (2012) The microtubule-stabilizing agent, epothilone D, reduces axonal dysfunction, neurotoxicity, cognitive deficits, and Alzheimer-like pathology in an interventional study with aged tau transgenic mice.J Neurosci. 32 (11): 3601-11.
8. Fitz, N.F. et al. (2012) Abca1 Deficiency Affects Alzheimer's Disease-Like Phenotype in Human ApoE4 But Not in ApoE3-Targeted Replacement Mice.J Neurosci. 32: 13125-36.
9. Habara, P. et al. (2012) Novel flow cytometric method for the detection of podocalyxin-positive elements in urine of patients with glomerulonephritides - first promising results.Folia Biol (Praha). 58: 57-63.
11. Kim, J.A. et al. (2015) Magnetic bead droplet immunoassay of oligomer amyloid ß for the diagnosis of Alzheimer's disease using micro-pillars to enhance the stability of the oil-water interface.Biosens Bioelectron. 67: 724-32.
12. Wilcock, D.M. et al. (2015) Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.Neurobiol Aging. 36 (9): 2468-74.
14. Hashitani, H. et al. (2015) Pacemaker role of pericytes in generating synchronized spontaneous Ca2+ transients in the myenteric microvasculature of the guinea-pig gastric antrum.Cell Calcium. 58 (5): 442-56.
15. Wilcock DM et al. (2015) Down syndrome individuals with Alzheimer's disease have a distinct neuroinflammatory phenotype compared to sporadic Alzheimer's disease.Neurobiol Aging. 36 (9): 2468-74.
16. Faraj SF et al. (2015) Assessment of tumoral PD-L1 expression and intratumoral CD8+ T cells in urothelial carcinoma.Urology. 85 (3): 703.e1-6.
17. Park, M.C. et al. (2016) Droplet-based magnetic bead immunoassay using microchannel-connected multiwell plates (µCHAMPs) for the detection of amyloid beta oligomers.Lab Chip. 16 (12): 2245-53.
18. Kanzaki, H. et al. (2017) Phosphoglycerol dihydroceramide, a distinctive ceramide produced by Porphyromonas gingivalis, promotes RANKL-induced osteoclastogenesis by acting on non-muscle myosin II-A (Myh9), an osteoclast cell fusion regulatory factor.Biochim Biophys Acta. 1862 (5): 452-462.